
A new cell therapy startup from an immunotherapy pioneer raises $175M in KRAS quest
Among the tussle in the biotech space to finally “solve” solid tumors, a quiet biotech is now taking its shot — and has some VCs and some big-name scientific prowess from Fred Hutch to back up its efforts.
Affini-T Therapeutics, aptly named for its emphasis on T cell therapy and armed with 57 employees across two lab spaces in Seattle and Boston, raised $175 million Tuesday to spend as the biotech sees fit — which at this point means building up its discovery platform and pushing candidates from its pipeline into clinical trials. According to the CEO, that money should last the company through December 2024, or about three years.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,600+ biopharma pros reading Endpoints daily — and it's free.